Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

LONDON - Sceptics have long argued that the United Kingdom is past its peak and trading largely on former glories. They point to the country's middli ...

LONDON: European shares hit a record high, gold was near one of its own all-time peaks and bond markets were back under ...

Stock markets rose Thursday on easing trade tensions and some strong company earnings, with London hitting a record high.

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

Stock markets mostly rose Thursday on easing trade tensions and some strong company earnings, with London and Frankfurt ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...